Soleno Therapeutics Inc (SLNO)

Over the past six months, Soleno Therapeutics' stock has experienced significant events. Key events impacting the stock include the FDA approval and commercial launch of VYKAT XR, leading to rapid profitability with $66.0 million in Q3 2025 revenue and $91.7 million in Q4 2025 revenue. Soleno achieved profitability with a positive net income of $20.9 million for the full year 2025 and generated $48.7 million of cash flow from operating activities in the fourth quarter of 2025. In November 2025, the company announced and invested $100 million in an accelerated share repurchase program. On April 5, 2026, Neurocrine Biosciences agreed to acquire Soleno Therapeutics through a cash tender offer of $53.00 per share, to be followed by a merger. A securities fraud lawsuit was filed against Soleno Therapeutics, Inc., alleging that the company downplayed or concealed safety concerns related to DCCR, including issues with excess fluid retention in clinical trial participants.

Information regarding demand seasonality for Soleno Therapeutics, Inc.'s products and services is not clearly defined. Given that VYKAT XR treats a rare genetic disorder, Prader-Willi Syndrome, it is less likely to be subject to typical seasonal demand patterns seen in other consumer-driven markets. The demand is likely driven by diagnosis and medical need rather than seasonal factors.

Soleno Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, operating within the Healthcare sector, specifically in the Biotechnology and Medical Research industry. Their lead product candidate, VYKAT XR (diazoxide choline extended-release tablets), received FDA approval on March 26, 2025, as the first FDA-approved therapy for hyperphagia in patients aged 4 years and older with Prader-Willi Syndrome (PWS). VYKAT XR, also known as DCCR, activates the KATP channel in the brain, pancreas, and fat tissue.

Soleno Therapeutics, Inc. is headquartered in Redwood City, California, United States. The company's primary market for VYKAT XR is currently the United States, where its commercial launch began in April 2025. Soleno also plans to pursue regulatory approval for VYKAT XR in other territories, starting with the European Union.

In the past year, Soleno Therapeutics has largely built a positive brand reputation through the successful FDA approval and commercial launch of VYKAT XR, which is the first approved therapy for hyperphagia in Prader-Willi Syndrome. The company rapidly achieved profitability and positive cash flow following the launch, indicating strong market acceptance and operational success. This success is further underscored by the acquisition offer from Neurocrine Biosciences. However, the company's reputation has been challenged by a securities fraud lawsuit filed against it, alleging that Soleno misrepresented or concealed significant safety concerns related to VYKAT XR (DCCR), specifically regarding excess fluid retention in clinical trial participants.

Soleno Therapeutics, Inc. has 250 institutional owners and shareholders holding a total of 63,819,325 shares. Major institutional owners include Fmr Llc, Janus Henderson Group Plc, BlackRock, Inc., Wellington Management Group Llp, Price T Rowe Associates Inc /md/, Vanguard Group Inc, Avoro Capital Advisors LLC, State Street Corp, Nantahala Capital Management, LLC, and Millennium Management Llc. Other notable institutional holders include Vivo Opportunity Fund Holdings, L.P., Adage Capital Management, L.P., Candriam Luxembourg S.C.A., T. Rowe Price Investment Management Inc., Invesco Ltd., SummitTX Capital L.P., Sphera Funds Management LTD., Balyasny Asset Management L.P., Russell Investments Group Ltd., Clark Capital Management Group Inc., Graham Capital Management L.P., and Sofinnova Investments Inc.